Pandemic Influenza Clinical Trial
Verified date | January 2014 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Belgium: Federal Agency for Medicines and Health Products, FAMHP |
Study type | Interventional |
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose
schedule in immunologically naïve adults against one vaccine formulation without adjuvant in
terms of tolerance and immunogenicity
Primary Objective:
To describe the safety profile and immunogenicity following each injection.
Status | Completed |
Enrollment | 251 |
Est. completion date | September 2010 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria : - Aged 18 to 40 years on day of inclusion - Informed consent form signed - Able to attend all scheduled visits and to comply with all trial procedures - For a woman, inability to bear a child or negative urine pregnancy test. Exclusion Criteria : - Participation in another clinical trial in the 4 weeks preceding the first trial vaccination. - Planned participation in another clinical trial during the present trial period. - Previous participation in a clinical trial involving an investigational flu pandemic vaccine. - Vaccination with an influenza vaccine during the past 6 months - Any vaccination in the 4 weeks preceding the first trial vaccination - Vaccination planned in the 4 weeks following any trial vaccination - Breast-feeding. - For a woman of child-bearing potential, the absence of an effective method of contraception or abstinence non observed for at least 4 weeks prior to the first vaccination and at least 4 weeks after the last vaccination. - Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy. - Known human immunodeficiency virus (HIV), hepatitis B (AgHBs) or hepatitis C seropositivity. - Known systemic hypersensitivity to egg proteins, chick proteins, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances. - Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. - Chronic illness at a stage that could interfere with trial conduct or completion. - Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures. - Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent. - Blood or blood-derived products received in the past 3 months. - Febrile illness (temperature = 37.5°C) on the day of inclusion. - Laboratory abnormalities considered clinically significant upon the Investigator's judgment in blood sample taken at screening (for Step 1 only) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To provide information concerning the safety of A/H5N1 Inactivated split influenza virus vaccine | Entire study period | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00976469 -
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00971542 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
Completed |
NCT00535665 -
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
|
Phase 2 | |
Completed |
NCT00950456 -
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
|
N/A | |
Completed |
NCT00908687 -
A/H5N1/LT Dose Ranging Study
|
Phase 2 | |
Completed |
NCT00783926 -
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
|
Phase 1 | |
Completed |
NCT00519389 -
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
|
Phase 1/Phase 2 | |
Recruiting |
NCT06046092 -
H7HLAII DNA Influenza Vaccine
|
Phase 1 | |
Completed |
NCT01640691 -
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01053143 -
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
|
Phase 3 | |
Completed |
NCT00660257 -
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
|
Phase 1 | |
Completed |
NCT00971906 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
Completed |
NCT00959465 -
A/H1N1 Immunogenicity and Safety in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT00971100 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
Completed |
NCT00970177 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
Completed |
NCT00532792 -
A/H5N1 Dose Ranging Study With Adjuvant Patch
|
Phase 1 | |
Withdrawn |
NCT00640211 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B
|
N/A | |
Withdrawn |
NCT00640874 -
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza
|
N/A | |
Withdrawn |
NCT00640302 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza
|
N/A |